CA3080587C — Use of oral octreotride compositions

USPTO Abstract

Described herein is the use of octreotide for treating a subject having acromegaly, wherein the octreotide is encapsulated in a capsule suitable for oral administration. In one aspect, there is provided a use of a pharmaceutical composition for treating a subject having acromegaly, wherein pharmaceutical composition comprises a suspension which comprises an admixture of a hydrophobic medium and a solid form, wherein the solid form comprises a therapeutically effective amount of octreotide and at least one salt of a medium chain fatty acid and a matrix forming polymer selected from dextran or polyvinylpyrrolidone (PVP), and wherein the medium chain fatty acid salt is present in the composition at an amount of 10% or more by weight, and wherein the pharmaceutical composition is suitable for oral administration.